Diabetic retinopathy causes preventable vision loss, yet most treatments are used only after damage appears. Fenofibrate, a pill used to lower blood fats, has drawn interest because earlier heart trials hinted at eye benefits, and the LENS trial in 2024 added more data. A new meta-analysis looked only at randomized trials to see where the evidence stands.
What the researchers did
Bhandari and colleagues searched four databases through June 25, 2026. Ten studies qualified: six completed with usable results and four still ongoing. Three completed trials, with 3,756 participants, contributed to the main analysis of retinopathy progression. Participants mostly had type 2 diabetes.
Key findings
- Fenofibrate lowered the risk of retinopathy progression by about 23% (risk ratio 0.77), or roughly 45 fewer progression events per 1,000 people, with moderate certainty.
- Need for retinal treatment appeared lower, but this rested mostly on one trial from before the anti-VEGF injection era, so the authors said it is not firm evidence about today’s care.
- No trial showed a benefit for visual acuity or visual function.
- Evidence on diabetic macular edema could not be combined.
- Blood clots in the veins were more common with fenofibrate in the FIELD trial (risk ratio 1.52).
The authors concluded that fenofibrate slows structural progression of diabetic retinopathy but is not established as vision-preserving.
What patients with diabetes should take from this
- Do not start or stop fenofibrate on your own; it is a prescription drug with its own risks, and the decision belongs with your primary doctor or endocrinologist.
- Blood sugar, blood pressure, and cholesterol control remain the foundation.
- Yearly dilated eye exams, or more often if advised, catch changes before vision drops.
Our role
At Khanna Vision Institute we screen for diabetic retinopathy, share findings with your physicians, and refer to retina specialists when treatment is needed. For more plain-language eye-care reading, see epilasikmd.com.
Source: Effect of fenofibrate on diabetic retinopathy progression: an RCT-Only systematic review and meta-analysis incorporating the LENS trial (Diabetes Research and Clinical Practice (PubMed), November 2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.